Bryan, Garnier & Co announces $275mn Galapagos IPO
15/05/2015 16:00
Bryan, Garnier & Co, the pan-European investment bank for growth companies, announced the successful USD 275 million Nasdaq IPO for Galapagos NV, a major European clinical-stage biotechnology company. The new shares were placed in a concurrent public offering in the US through ADSs at a price of USD 42.05 and private placement in Europe at a price of 37 euros per share. It is the largest Nasdaq IPO of a European biotech and one of three largest biotech IPO ever in Europe or in the US. Bryan, Garnier & Co acted as co-manager and sole European investment bank, alongside Morgan Stanley, Credit Suisse, Cowen and Company and Nomura.
15/05/2015 16:00
Bryan, Garnier & Co, the pan-European investment bank for growth companies, announced the successful USD 275 million Nasdaq IPO for Galapagos NV, a major European clinical-stage biotechnology company. The new shares were placed in a concurrent public offering in the US through ADSs at a price of USD 42.05 and private placement in Europe at a price of 37 euros per share. It is the largest Nasdaq IPO of a European biotech and one of three largest biotech IPO ever in Europe or in the US. Bryan, Garnier & Co acted as co-manager and sole European investment bank, alongside Morgan Stanley, Credit Suisse, Cowen and Company and Nomura.
